专利检索_磺酸其卤化物酯或酐专利检索_磺酸其卤化物酯或酐专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
141	OXIME SULFONATE AND N-OXYIMIDOSULFONATE PHOTOACID GENERATORS AND PHOTORESISTS COMPRISING SAME	PCT/US0126526	2001-08-24	WO0217019A3	2002-08-22	CAMERON JAMES F; POHLERS GERHARD
New photoacid generator compounds ("PAGs") are provided and photoresist compositions that comprise such compounds. In particular, non-ionic PAGs are provided that contain an oxime sulfonate group, and/or an N-oxyimidosulfonate group. PAGs of the invention are particularly useful as photoactive components of photoresists imaged at short wavelenghts such as 248 nm, 193 nm and 157 nm.
142	A MULTISTAGE PROCESS FOR THE PREPARATION OF HIGHLY PURE DEFEROXAMINE MESYLATE SALT	PCT/US2000/032574	2000-11-30	WO01040164A1	2001-06-07
The present invention provides a purification process whereby deferoxamine B produced by a microorganism and in mixture with other polyhydroxamates produced by the microorganism may be converted into its mesylate salt substantially free of the other polyhydroxamates and substantially free of chloride ion. The process includes adsorption and desorption of the deferoxamine B on an adsorption resin, direct precipitation of the deferoxamine free base out of the eluent from the adsorption resin, contacting of the deferoxamine B free base with methanesulfonic acid and isolation of the deferoxamine B mesylate salt by precipitation. This process minimizes decomposition of deferoxamine B.
143	MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS	PCT/US2000/016988	2000-06-21	WO00078145A1	2000-12-28
Macrophage scavenger receptor antagonists are provided. Methods of treating cardiovascular disease comprising administration of the present compounds are also provided. The present compounds inhibit lipid accumulation within macrophage-derived foam cells.
144	N-SUBSTITUTED SULFONAMIDE DERIVATIVES	PCT/US1999/017017	1999-07-28	WO00006537A1	2000-02-10
The present invention provides certain N-substituted sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
145	INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES	PCT/US1998/009297	1998-05-07	WO98050030A1	1998-11-12
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2-, and (i) heterocyclic-L2-; R2 is selected from (a) (Ia), (b) -C(O)NH-CH(R14)-C(O)OR15, (c) (Ib), (d) -C(O)NH-CH(R14)-C(O)NHSO2R16, (e) -C(O)NH-CH(R14)-tetrazolyl, (f) -C(O)NH-heterocyclic, and (g) -C(O)NH-CH(R14)-C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, (Ic), and -P(W)RR; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) -L4-N(R5)-L5-, (b) -L4-O-L5-, (c) -L4-S(O)n-L5-, (d) -L4-L6-C(W)-N(R5)-L5-, (e) -L4-L6-S(O)m-N(R5)-L5-, (f) -L4-N(R5)-C(W)-L7-L5-, (g) -L4-N(R5)-S(O)p -L7-L5-, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene, (k) a covalent bond, (l) (Id), and (m) (Ie) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
146	INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES	PCT/US1998/009296	1998-05-07	WO98050029A1	1998-11-12
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) lower alkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl -L2-, and (i) heterocyclic -L2-; R2 is selected from (a) formula (1), (b) -C(O)NH-CH(R14)-C(O)OR15, (c) formula (2), (d) -C(O)NH-CH(R14)-C(O)NHSO2R16, (e) -C(O)NH-CH(R14)-tetrazolyl, (f) -C(O)NH-heterocyclic, and (g) -C(O)NH-CH(R14)-C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, formula (3), and -P(W)RR; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylalkyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) -L4-N(R5)-L5-, (b) -L4-O-L5-, (c) -L4-S(O)n-L5-, (d) -L4-L6-C(W)-N(R5)-L5-, (e) -L4-L6-S(O)m-N(R5)-L5-, (f) -L4-N(R5)-C(W)-L7-L5-, (g) -L4-N(R5)-S(O)p-L7-L5-, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene, (k) a covalent bond, (1) formula (4), and (m) formula (5) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
147	USE OF UNSATURATED ALDEHYDES IN DYING FIBERS CONTAINING KERATIN	PCT/EP1998/002243	1998-04-16	WO98047473A1	1998-10-29
The invention relates to the use of unsaturated aldehydes of formulae (Ia) or (Ib), wherein R<1>, R<2>, R<3> and R<4> independently mean hydrogen, halogen, a C1-C4-alkoxy, C1-C4-alkyl, aryl radical or a C1-C4-alkoxy-C1-C4-aryl radical and n stands for 1 or 2, wherein R<1> and R<2>, R<1> and R<3>, R<2> and R<3> and R<2> and R<4> can form together with a residual molecule a ring with 5 to 7 units when n equals 1, in addition to the corresponding mono, bis or omega -alkoxy acetals, for the dying of fibers containing keratin, specially human hair.
148	Aminoguandines and alkoxyguandines as protease inhibitors	PCT/US9721649	1997-11-26	WO9823565A3	1998-07-30	TOMCZUK BRUCE E; SOLL RICHARD M; LU TIANBAO; FEDDE CYNTHIA L; ILLIG CARL R; MARKOTAN THOMAS P; STAGNARO THOMAS P
Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula:wherein X is O or NR<9 >and R<1>-R<4>, R<6>-R<9>, R<11>, R<12>, R, R, R, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.
149	PROCESS FOR PURIFYING ALKANESULFONIC ANHYDRIDE AND PROCESS FOR PRODUCING ALKANESULFONIC ACID USING THE PURIFIED ALKANESULFONIC ANHYDRIDE	PCT/EP2018/059864	2018-04-18	WO2018192954A1	2018-10-25	WORTMANN, Juergen; SPIELMANN, Jan; FEDERSEL, Katharina; RUETHER, Feelly
The invention relates to a process for purifying alkanesulfonic anhydride which comprises the following steps of: (a) feeding a stream comprising alkanesulfonic anhydride, sulfuric acid, high boilers and residual low boilers into a melt crystallization (25) to form crystals of the alkanesulfonic anhydride suspended in mother liquor, (b) performing a solid-liquid separation to remove the crystals from the mother liquor, (c) optionally washing the crystals to remove mother liquor adhering to the crystals. The invention further relates to processes for producing alkanesulfonic acid using the purified alkanesulfonic anhydride.
150	A CATALYTIC LIQUEFACTION (CTL) METHOD FOR PRODUCTION OF BIO-CRUDE OIL USING IONIC LIQUID CATALYST AND PREPARATION THEREOF	PCT/IN2017/050303	2017-07-25	WO2018020511A1	2018-02-01	ARVIND Mallinath Lali; PAWAR, Hitesh Suresh; SHRAVAN, Sreenivasan
The present disclosure relates to a sulfonate-based ionic liquid. A simple process for obtaining the ionic liquid is provided. The conversion of waste into a usable bio-crude oil via a liquefaction process is further described, where the ionic liquid is employed as a catalyst.
151	PROCEDE DE PREPARATION DE DERIVES OXYSULFURES ET FLUORES EN MILIEU LIQUIDE IONIQUE	PCT/EP2015/078758	2015-12-07	WO2016091772A1	2016-06-16	METZ, François
La présente invention concerne un procédé de préparation d'un dérivé oxysulfuré et fluoré sous forme de sel de formule (II) Ea-SOO^-Q⁺ (II) comprenant la mise en présence d'un composé liquide ionique de formule (I) à l'état liquide Ea-COO^-Q⁺ (I) - Ea représentant l'atome de fluor ou un groupe ayant de 1 à 10 atomes de carbone choisi parmi les fluoroalkyles, les perfluoroalkyles et les fluoroalkényles; et - Q⁺ représentant un cation onium, avec un oxyde de soufre, ledit composé liquide ionique de formule (I) représentant au moins 50 % en poids du milieu réactionnel liquide initial.
152	PROCEDE DE PREPARATION DE DERIVES OXYSULFURES ET FLUORES EN PRESENCE D'UN SOLVANT ORGANIQUE	PCT/EP2015/078756	2015-12-07	WO2016091771A1	2016-06-16	DAMBRIN, Valery; REVELANT, Denis
La présente invention concerne un procédé de préparation d'un dérivé oxysulfuré et fluoré de formule (III) Ea-SO₃R (III) comprenant la mise en contact, en présence d'un solvant organique aprotique polaire, d'un composé de formule (II) Ea-SOOR (II) - Ea représentant l'atome de fluor ou un groupe ayant de 1 à 10 atomes de carbone choisi parmi les fluoroalkyles, les perfluoroalkyles et les fiuoroalkényles; et - R représentant l'hydrogène, un cation monovalent ou un groupe alkyle; avec un agent oxydant.
153	CYCLIC PROCESS FOR THE PRODUCTION OF TAURINE FROM ETHYLENE OXIDE	PCT/US2015/000061	2015-05-20	WO2015183343A1	2015-12-03	HU, Songzhou
The present invention discloses a cyclic process for the production of taurine from ethylene oxide in a high yield of greater than 95% by continuously converting the byproducts of the ammonolysis reaction, sodium ditaurinate and sodium tritaurinate, to sodium taurinate. The cyclic process is completed by using sulfur dioxide or sulfurous acid to neutralize sodium taurinates to recover taurine and to regenerate sodium bisulfite, which is then reacted with ethylene oxide.
154	SURFACTANT COMPOSITIONS	PCT/EP2012/002705	2012-06-27	WO2013000571A1	2013-01-03	JAKOBS-SAUTER, Britta; SCHROEDER, Clemens; BREITZKE, Burkhard; SCHOENKAES, Udo; GIUFFRIDA, Giuseppe; MATHESON, Lee; KINSLEY, Kermit; COX, Michael; RUSSEL, Geoffrey Lynn; WINDER, John Barry
A surfactant composition comprising alkylarylsulfonate molecules wherein more than 30 wt.% of the alkylarylsulfonate molecules of the surfactant composition are one or more species of the formula: [R - X - Ar (SO₃)^-]_a [Mⁿ⁺]_b wherein: X is a linear acyclic aliphatic hydrocarbyl chain; R is bound to a non-terminal carbon atom of X and is selected from H and C1, C2, and C3 alkyl groups; X and R together have 9 or 10 carbon atoms; Ar is an aromatic group; M is a cation, n is selected from 1,2 and 3; and a and b are selected such that the alkylarylsulfonate molecule is electroneutral, wherein more than 20 wt.% of the alkylaryl molecules of the surfactant composition have an R which is methyl or ethyl.
155	METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO	PCT/US2009/054067	2009-08-17	WO2010022001A1	2010-02-25	UMEMOTO, Teruo; SINGH, Rajendra P.
Novel preparative methods for fluoroalkyl arylsulfinyl compounds are disclosed. Fluorinated compounds as useful fluorinated compounds, intermediates, or builing blocks are disclosed. Useful applications of the fluoroalkyl arylsulfinyl compounds are shown.
156	ELECTROPLATING ADDITIVE FOR THE DEPOSITION OF METAL, A BINARY, TERNARY, QUATERNARY OR PENTANARY ALLOY OF ELEMENTS OF GROUP 11 (IB)-GROUP 13 (IIIA) -GROUP 16 (VIA)	PCT/EP2009/003885	2009-05-29	WO2009144036A1	2009-12-03	VOSS, Torsten; SCHULZE, Jörg; KIRBS, Andreas; SÖNMEZ, Aylin; BRUNNER, Heiko; FRÖSE, Bernd; ENGELHARDT, Ulrike
The invention relates to electroplating additives for the deposition of a group¹¹(IB) metal/binary or ternary group ¹¹(IB)-group¹³(IIIA)ternary, quaternary or pentanary group ¹¹(IB)-group¹³(IllA)-group¹⁶(VIA)-alloy on substrates useful for thin film solar cells. The additives have the general formula (A): wherein X₁ and X₂ may be the same or different and are selected from the group consisting of arylene and heteroarylene; FG₁ and FG₂may be the same or different or are selected from the group consisting of -S(O)2OH, -S(O)OH, -COOH, -P(O)₂OH and primary, secondary and tertiary amino groups and salts and esters thereof; R is selected from the group consisting of alkylene, arylene or heteroarylene and n and m are integers from 1 to 5.
157	CRYSTALLINE FORMS OF THE DI-SODIUM SALT OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID	PCT/US2006036455	2006-09-18	WO2007035718A3	2009-06-18	DHOOT NIKHIL; BAY WILLIAM ELLIOT; DINH STEVEN; MAJURU SHINGAI; CORVINO JOANNE P; O'TOOLE DORIS C
The present invention relates to crystalline polymorphic forms of the di- sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same.
158	ANTIMICROBIAL MATERIALS AND PREPARATION THEREOF	PCT/IN2008000553	2008-09-01	WO2009072144A2	2009-06-11	AGARWAL UDAY SHANKAR; THAMPI SUMESH; JAIN ASHWIN KUMAR
The invention relates to a monomelic antimicrobial agent, to a copolymer and polymer compositions having antimicrobial activity and to articles and products prepared from them. The invention also relate to methods for preparing the anti microbial copolymer and polymer compositions. The monomeric antimicrobial agent of the invention has the general formula (R)j-(SO3MM)m(L)n where j, l, m is an integer from 1 to 6, n is an integer from 0 to 6, M is a metal selected from Ag, Cu or Zn, L is a nitrogen, phosphorus or sulphur containing ligand selected from ammonia, an amine, pyridine, imidazole, pyrazole, triaryl phosphine, trialkyl phosphine, triaryl phosphate, trialkyl phosphate or a thiol, R is a linear or branched unsubstituted or substituted alkyl or alkenyl, an aryl or a substituted aryl carrying at least one reactive functional group.
159	Histone Deacetylase Inhibitors	PCT/US2007062152	2007-02-14	WO2007095584A3	2009-05-22	BRADNER JAMES ELLIOT; MAZITSCHEK RALPH
In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for exmaple. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.
160	APPLICATIONS OF UBIQUINONES AND UBIQUINOLS	PCT/US2008/062123	2008-04-30	WO2008134766A1	2008-11-06	FAIN, Randy; MCCABE, Jake
The present invention relates to cell culture medium compositions comprising lipophilic compounds and solubilizing agent and methods of using such compositions for the culturing of cells. The invention also relates to methods of treating disorders of the nervous system such as peripheral neuropathy.

3 4 5 6 7 8 9 10 11 12

该功能需要专业版企业版VIP权限，您可以：